<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Urine-derived human chorionic gonadotropin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Urine-derived human chorionic gonadotropin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Urine-derived human chorionic gonadotropin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11606" href="/d/html/11606.html" rel="external">see "Urine-derived human chorionic gonadotropin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13392" href="/d/html/13392.html" rel="external">see "Urine-derived human chorionic gonadotropin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F151099"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Novarel;</li>
<li>Pregnyl</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866322"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Pregnyl</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F151114"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gonadotropin;</li>
<li>
                        Ovulation Stimulator</li></ul></div>
<div class="block doa drugH1Div" id="F151101"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b5be25e-b967-44da-b12d-97b32f9e2918">Hypogonadotropic hypogonadism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypogonadotropic hypogonadism: </b> Males: <b>IM:</b> Various regimens:</p>
<p style="text-indent:-2em;margin-left:4em;">500 to 1,000 units 3 times/week for 3 weeks, followed by the same dose twice weekly for 3 weeks <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">4,000 units 3 times/week for 6 to 9 months, then reduce dosage to 2,000 units 3 times/week for additional 3 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1473d681-cecf-4aa4-9b27-de75ad3de13d">Ovulation induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovulation induction: IM:</b> 5,000 to 10,000 units 1 day following last dose of menotropins.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00762ce2-3918-47a8-89c7-6e7d2c4f9d5a">Spermatogenesis induction associated with hypogonadotropic hypogonadism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spermatogenesis induction associated with hypogonadotropic hypogonadism (off-label use): IM, SUBQ:</b> 1,000 to 2,000 units 2 to 3 times/week. Administer chorionic gonadotropin (human) (hCG) until serum testosterone levels are normal (may require 2 to 3 months of therapy), then may add menopausal gonadotropin or FSH if needed to induce spermatogenesis; continue hCG at the dose required to maintain testosterone levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15260010','lexi-content-ref-30194850','lexi-content-ref-1712735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15260010','lexi-content-ref-30194850','lexi-content-ref-1712735'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990379"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987767"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F151102"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F151109"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13392" href="/d/html/13392.html" rel="external">see "Urine-derived human chorionic gonadotropin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9a73c870-9dc5-424b-a0f2-181cee06e264">Hypogonadotropic hypogonadism, puberty induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypogonadotropic hypogonadism, puberty induction:</b> Limited data available: Children ≥12 years and Adolescents: Males: IM: 500 to 3,000 units 2 to 3 times weekly; adjust dose based on serum testosterone levels, every 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15260010','lexi-content-ref-26019400','lexi-content-ref-Sperling.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15260010','lexi-content-ref-26019400','lexi-content-ref-Sperling.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad0fc183-5eec-4abe-a7e1-ac3d7a01fa8c">Prepubertal cryptorchidism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prepubertal cryptorchidism:</b>
<b>Note:</b> Although FDA approved, routine use of hormonal therapy to induce testicular descent is not recommended by experts due to low response rates, and long-term efficacy evidence is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24857650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24857650'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents: Males: IM: Various regimens reported by manufacturer:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Therapy is usually instituted between the ages of 4 and 9 years:</p>
<p style="text-indent:-2em;margin-left:8em;">4,000 units 3 times weekly for 3 weeks <b>or</b></p>
<p style="text-indent:-2em;margin-left:8em;">5,000 units every second day for 4 injections <b>or </b></p>
<p style="text-indent:-2em;margin-left:8em;">500 units 3 times weekly for 4 to 6 weeks (if not successful, may repeat course one month later using 1,000 units/dose) <b>or </b></p>
<p style="text-indent:-2em;margin-left:8em;">15 injections of 500 to 1,000 units administered over 6 weeks.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084767"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51084768"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F151079"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia, precocious puberty</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastalgia, ovarian hyperstimulation syndrome (including ovarian cyst, rupture of ovarian cyst)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, fatigue, headache, irritability, restlessness</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ovarian torsion, testicular neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema)</p></div>
<div class="block coi drugH1Div" id="F151091"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Prior hypersensitivity to chorionic gonadotropin, including human chorionic gonadotropin (hCG), or any component of the formulation; tumors of the hypothalamus, pituitary gland, ovary, breast (females or males), uterus, prostate.</p>
<p style="text-indent:-2em;margin-left:2em;">Novarel (additional contraindications): Precocious puberty.</p>
<p style="text-indent:-2em;margin-left:2em;">Pregnyl (additional contraindications): Elevated serum follicle-stimulating hormone; uncontrolled nongonadal endocrinopathies (eg, thyroid, adrenal, pituitary disorders); malformations of the reproductive organs incompatible with pregnancy; fibroid tumors of the uterus incompatible with pregnancy; abnormal vaginal bleeding of unexplained origin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Prepubertal males with signs of anatomical. obstruction</p></div>
<div class="block war drugH1Div" id="F151076"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Concerns related to adverse effects:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylaxis has been reported with urinary-derived human chorionic gonadotropin (hCG) products.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian neoplasms: Benign and malignant neoplasms have been reported (infrequently) in women receiving multiple-drug therapy for controlled ovarian stimulation; causal effect has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian torsion: Has been reported following gonadotropin treatment; may be related to ovarian hyperstimulation syndrome (OHSS), prior ovarian torsion, prior or current ovarian cyst, polycystic ovaries, pregnancy, or prior abdominal surgery. Early diagnosis and prompt detorsion may limit the extent of ovarian damage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary effects: Serious pulmonary conditions (eg, atelectasis, acute respiratory distress syndrome) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Arterial or venous thromboembolism may occur; patients with a history of family history of thrombosis, severe obesity, or thrombophilia are at an increased risk.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use with caution in patients with asthma; hCG may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease; hCG may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cryptorchidism: May induce precocious puberty in children being treated for cryptorchidism; discontinue if signs of precocious puberty occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use with caution in patients with a history of migraines; hCG may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; hCG may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorders; hCG may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: <b>Not</b> effective adjunctive therapy in the treatment of obesity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovulation induction: Appropriate use: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management. May cause OHSS. OHSS is a rare, exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; Shmorgun 2017). Multiple births may result from the use of these medications; advise patients of the potential risk of multiple births before starting the treatment. Risk of ectopic pregnancy or spontaneous abortion may be increased.</p></div>
<div class="block foc drugH1Div" id="F151085"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Novarel: 5000 units (1 ea); 10,000 units (1 ea) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pregnyl: 10,000 units (1 ea) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pregnyl: 10,000 units (1 ea) [contains benzyl alcohol, sodium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10,000 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F151072"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F151092"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Chorionic Gonadotropin Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 unit (per each): $374.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Novarel Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000 unit (per each): $194.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 unit (per each): $389.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Pregnyl Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 unit (per each): $204.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866323"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pregnyl: 10,000 units (10 mL) [contains benzyl alcohol]</p></div>
<div class="block adm drugH1Div" id="F151088"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> For IM administration.</p>
<p style="text-indent:-2em;margin-left:2em;">May be administered SUBQ for spermatogenesis induction associated with hypogonadotropic hypogonadism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30194850','lexi-content-ref-1712735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30194850','lexi-content-ref-1712735'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612415"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer IM only.</p></div>
<div class="block hazard drugH1Div" id="F49130928"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020). <b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F151087"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypogonadotropic hypogonadism:</b> Treatment of hypogonadism secondary to a pituitary deficiency in males.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovulation induction:</b> Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not caused by primary ovarian failure, and who has been appropriately treated with human menotropins.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prepubertal cryptorchidism:</b> Treatment of prepubertal cryptorchidism not caused by anatomic obstruction.</p></div>
<div class="block off-label drugH1Div" id="F28843702"><span class="drugH1">Use: Off-Label: Adult</span><p>Spermatogenesis induction associated with hypogonadotropic hypogonadism</p></div>
<div class="block cyt drugH1Div" id="F13299037"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F151080"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F49296626"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">When needed for ovulation induction, should only be used by physicians who are thoroughly familiar with infertility problems and their management. Multiple births may result from use of this medication.</p>
<p style="text-indent:0em;margin-top:2em;">When administered for spermatogenesis induction associated with hypogonadotropic hypogonadism in patients planning a pregnancy, also evaluate fertility status of the female partner (AACE [Petak 2002]). Treatment with chorionic gonadotropin (human) is continued after conception and may be continued after a successful pregnancy if an additional pregnancy is desired in the future (Prior 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Testicular tumors in otherwise healthy patients have been reported when treating secondary infertility.</p></div>
<div class="block pri drugH1Div" id="F2998838"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Studies in animals have shown evidence of fetal abnormalities at doses intended to induce superovulation (used in combination regimens).</p></div>
<div class="block brc drugH1Div" id="F20613577"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if chorionic gonadotropin (human) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering chorionic gonadotropin (human) to patients who are breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F2998840"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Hypogonadotropic hypogonadism: Serum testosterone levels, semen analysis (AACE [Petak 2002]).</p>
<p style="text-indent:-2em;margin-left:2em;">Ovulation induction:</p>
<p style="text-indent:-2em;margin-left:4em;">Monitor sufficient follicular growth and maturation. This may be directly estimated by transvaginal sonographic visualization of the ovaries and endometrial lining. The combination of both ultrasonography and measurement of estradiol levels is useful for monitoring for the growth and development of follicles and timing human chorionic gonadotropin (hCG) administration.</p>
<p style="text-indent:-2em;margin-left:4em;">The clinical evaluation of estrogenic activity (changes in vaginal cytology and changes in appearance and volume of cervical mucus) provides an indirect estimate of the estrogenic effect upon the target organs and, therefore, it should only be used adjunctively with more direct estimates of follicular development (ultrasonography and serum estradiol determinations).</p>
<p style="text-indent:-2em;margin-left:4em;">The clinical confirmation of ovulation is obtained by direct and indirect indices of progesterone production as well as sonographic evidence of ovulation. Direct or indirect indices of progesterone production most generally used are: rise in serum or urine luteinizing hormone, rise in basal body temperature, increase in serum progesterone, and menstruation following the shift in basal body temperature. Sonographic evidence of ovulation includes collapsed follicle, fluid in the cul-de-sac, features consistent with corpus luteum formation, and secretory endometrium.</p>
<p style="text-indent:-2em;margin-left:4em;">Monitor for signs and symptoms of ovarian hyperstimulation syndrome for at least 2 weeks following hCG administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Ovarian hyperstimulation syndrome: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (all daily or as necessary), and liver enzymes (weekly) (Shmorgun 2017).</p></div>
<div class="block pha drugH1Div" id="F151075"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Human chorionic gonadotropin (hCG) is produced by the human placenta; available preparations provide purified luteinizing hormone obtained from the urine of pregnant women. hCG stimulates production of gonadal steroid hormones by causing production of androgen by the testes and the development of secondary sex characteristics in males. In females, hCG acts as a substitute for luteinizing hormone (LH) to stimulate ovulation.</p></div>
<div class="block phk drugH1Div" id="F151090"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;">Duration: IM: ~36 hours</p>
<p style="text-indent:0em;">Distribution: Distributes mainly into the testes in males and into the ovaries in females</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Biphasic: Initial: 6 to 11 hours; Terminal: 23 to 37 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: IM: Within 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~10% to 12 %) within 24 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F151093"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choriomon | Physex | Pregnyl | Primogonyl | Profasi</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Endocorion | Gonacor | Pregnyl | Profasi HP</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Profasi | Zivafert</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">A p l | Choriomon | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Hcg | Physex | Pregnyl</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Choriomon m | Pregnyl | Profasi HP</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Choriomon</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Hucog hp</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">A p l | Gonapin | Pregnyl</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Chorion.gonadotrop | Chorionic gonadotr | Pregnyl | Profasi | Puberogen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choriomon | Gonagam hcg | Primogonyl | Profasi HP | Prolugyn</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Brevactid | Praedyn | Pregnyl | Profasi | Zivafert</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Brevactid | Predalon | Pregnesin | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Corgon | Endocorion | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Gonacor | Pregnyl | Primogonyl</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Brevactid | Choriomon | Gonasi hp | Predalon | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choriomon | Epifasi | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Gonasi kit | Hcg lepori | Profasi</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Hucog | Pubergen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Gonasi set | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Gonadotrophine chorionique endo | Pregnyl</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Pregnyl | Profasi | Puberogen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Chorapur | Choriogonin | Pregnyl | Profasi | Zivafert kit</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Chorigon | Pregnyl</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choriolife | Choriotec | Coehcg hp | Corion | Coriosurge hp | Coriosurge xp | Corlova | Eema hp | Eutrig hp | Fertigyn | Folliglan cg | Htrop | Hucog | Hucog hp | Humosar hp | Ivf-c | Koragon | Koragon hp | Lg ivf-c | Life | Materna Hcg | Neo hcg | Origen | Ovidac | Ovidrel | Ovulate-c | Ovunal HP | Ovutrig hp | Pregnyl | Profasi | Proficent | Provigil | Pubergen | Pubergen hp | Pubergen Jo | Pubergen nano | Pure hcg | Puretrig | Sifasi HP | Stimogon | Trigova hp | Zyhcg</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Gonasi hp | Pregnyl</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choriomon | Gonacor | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gestoron | Gonatropin | H c g fuji seiyaku | H c g mochida | P.u.g. hormone | Primogonyl | Profacy | Puberogen | Trophoblastin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Eutrig hp | Hucog | Pregnyl | Pubergen</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Ivf-c | Pregnyl | Profasi | Puberogen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choriomon | Ivf-c | Pregnyl</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Diclair HP HCG | Gonadotrophine | Pregnyl | Profasi | Profasi HP</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Gonadotropin chorionic | Praedyn | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Brevactid | Choragon | Choriomon | Gonasi hp | Praedyn | Predalon | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choriomon | Gonadotropyl c | Gonasone | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Hucog | Pregnyl | Profasi | Pubergen</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Gona max</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Gonasi | Pregnyl | Profasi | Profasi 10000</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Gonasi hp | Gonasi set | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Coriomek | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Ferti c | Ghc | Gonacor | Ivf-c | Physex | Pregnyl | Presage | Profasi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Eutrig hp | Praedyn | Pregnyl | Profasi | Zivafert</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Apl | Chorionic gonadotropin | Novarel | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Profasi HP</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Gonacor</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Pregnyl</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Brevactid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choral | Ecostimulin | Gonadotrophin chorionic | Gonadotropin chorionic | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Chorapur | Choriomon | Epifasi | Pregnyl | Primogonyl | Profasi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Gonasi set | Pregnyl</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Primogonyl | Profasi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Gonasi kit | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Physex | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Diclair HP HCG | Gonadotrophine chorionique endo | Profasi</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Choragon | Choriomon | Pregnyl | Profasi HP</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Chorex | Forstrong lyo | Gona-Hormon | Hcg | Ovulatone | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Choriomon | Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Epifasi | Hucog</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Gonacor | Pregnyl | Profasi HP | Proganol | Progon</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pregnyl | Profasi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">A p l | Pregnyl | Profasi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25574681">
<a name="25574681"></a>Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/25574681/pubmed" id="25574681" target="_blank">25574681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531097">
<a name="22531097"></a>Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/22531097/pubmed" id="22531097" target="_blank">22531097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24857650">
<a name="24857650"></a>Kolon TF, Herndon CD, Baker LA, et al; American Urological Association. Evaluation and treatment of cryptorchidism: AUA guideline. <i>J Urol</i>. 2014;192(2):337-345. doi:10.1016/j.juro.2014.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/24857650/pubmed" id="24857650" target="_blank">24857650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22416285">
<a name="22416285"></a>Novarel (chorionic gonadotropin) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc; May 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/22416285/pubmed" id="22416285" target="_blank">22416285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15260010">
<a name="15260010"></a>Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. <i>Endocr Pract</i>. 2002;8(6):440-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/15260010/pubmed" id="15260010" target="_blank">15260010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678032">
<a name="27678032"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi:10.1016/j.fertnstert.2016.08.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/27678032/pubmed" id="27678032" target="_blank">27678032</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pregnyl (chorionic gonadotropin) [prescribing information]. Jersey City, NJ: Organon USA LLC; June 2023.</div>
</li>
<li>
<div class="reference">
                  Pregnyl (chorionic gonadotropin) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30194850">
<a name="30194850"></a>Prior M, Stewart J, McEleny K, Dwyer AA, Quinton R. Fertility induction in hypogonadotropic hypogonadal men. <i>Clin Endocrinol (Oxf)</i>. 2018;89(6):712-718. doi:10.1111/cen.13850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/30194850/pubmed" id="30194850" target="_blank">30194850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1712735">
<a name="1712735"></a>Saal W, Glowania HJ, Hengst W, Happ J. Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin. <i>Fertil Steril</i>. 1991;56(2):225-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/1712735/pubmed" id="1712735" target="_blank">1712735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26019400">
<a name="26019400"></a>Sato N, Hasegawa T, Hasegawa Y, et al. Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols. <i>Clin Pediatr Endocrinol</i>. 2015;24(2):37-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/26019400/pubmed" id="26019400" target="_blank">26019400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29080733">
<a name="29080733"></a>Shmorgun D, Claman P. No-268-The diagnosis and management of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2017;39(11):e479-e486. doi: 10.1016/j.jogc.2017.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/urine-derived-human-chorionic-gonadotropin-drug-information/abstract-text/29080733/pubmed" id="29080733" target="_blank">29080733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sperling.1">
<a name="Sperling.1"></a>Sperling MA, ed. <i>Pediatric Endocrinology</i>. 4th ed. Canada: Elsevier; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9249 Version 206.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
